This information is from Law MR, Wald NJ, Rudnicka AR (2003) Quantifying effect of statins on low-density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 326: 1423. Finding more information and committee details To find NICE guidance on related topics, including guidance in development, see the NICE topic page on cardiovascular conditions. For full details of the evidence and the guideline committee's discussions, see the full guideline. You can also find information about how the guideline was developed, including details of the committee. NICE has produced tools and resources to help you put this guideline into practice. For general help and advice on putting our guidelines into practice, see resources to help you put NICE guidance into practice. Update information February 2023: We have added a new recommendation on aspirin for primary prevention of CVD. This is based on a 2023 surveillance decision. September 2016: Recommendation 1.4.28 was amended to clarify what was meant by high-intensity statin treatment, and that the recommendation applies to both primary and secondary prevention. The term 'high-intensity statin' was also added to the terms used in this guideline section and linked to throughout. January 2015: New section on implementation: getting started added. July 2014: This guideline updated and replaced NICE guideline CG67 (published September 2008). It also updated and replaced recommendations relating to statin therapy for people at increased risk of developing cardiovascular disease or those with established cardiovascular disease in statins for the prevention of cardiovascular events (NICE technology appraisal guidance 94, 2006). Recommendations marked [2014] last had an evidence review in 2014. Recommendations marked [2008] or [2008, amended 2014] last had an evidence review in 2008. In some cases, minor changes were made to the wording to bring the language and style up to date, without changing the meaning. 